Prospective Treatment of Age-Related Diseases by Slowing Down Aging

Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute

Mikhail (Misha) V.  Blagosklonny, MD, PhD, has been appointed Member/Professor of Oncology at Roswell Park Cancer Institute, Buffalo, NY. His appointment started April 15, 2009. Dr. Blagosklonny is an author of over 170 research articles, reviews and book chapters. He is Founding Editor and Editor-in-Chief of Cell Cycle and also Associate Editor of Cancer Biology & Therapy, Cancer Research, Cell Death & Differentiation, Autophagy, International Journal of Cancer, American Journal of Pathology, and PLOS ONE. His research interests range from 
Cellular senescence happens in 2 steps: cell cycle arrest followed, or sometimes preceded, by gerogenic conversion (geroconversion). Geroconvesrion is a form of growth, a futile growth during cell cycle arrest. It converts reversible arrest to irreversible senescence. Geroconversion is driven by growth-promoting, mitogen-/nutrient-sensing pathways such as mTOR. Geroconversion leads to hyper-secretory, hypertrophic and pro-inflammatory cellular phenotypes, hyperfunctions and malfunctions. On organismal level, geroconversion leads to age-related diseases 
https://www.onacademic.com/search/list.html?q=Blagosklonny

When public mention modern medicine, precision plays one of the most crucial roles and human lives are directly dependent on it. Hence, any researches related to medicine are required to comply with the highest standards. The challenge today is that any outcomes of researches can be posted online and used as a reference without being precisely checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That assists both readers and authors to quality-check publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website has a complete publications list with respective scores higher than 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it provides the necessary help to anybody, who has interest in oncology.
https://www.semanticscholar.org/author/Zoya-N.-Demidenko/4772760
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was published back in 2018 by Oncotarget and written by different experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The article has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to understand the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hence, the article about melanoma, was used for citations in different news articles 69 times. Besides that, it was mentioned in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This publication has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have come across a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is proud to have the ability to share with online viewers this highly appreciated and high-quality information, that is trustworthy and reliable.
https://www.apollo.io/people/Misha/Blagosklonny/57de39efa6da987b015ccadb

Comments

Post a Comment

Popular posts from this blog

Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis

Image
Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis ABSTRACT The survival of patients with advanced osteosarcoma is poor with limited therapeutic options. There is an urgent need for new targeted therapies based on biomarkers. Recently, theranostic molecular profiling services for cancer patients by CLIA-certified commercial companies as well as in-house profiling in academic medical centers have expanded exponentially. We evaluated molecular profiles of patients with advanced osteosarcoma whose tumor tissue had been analyzed by one of the following methods: 1. 182-gene next-generation exome sequencing (Foundation Medicine, Boston, MA), 2. Immunohistochemistry (IHC)/PCR-based panel (CARIS Target Now, Irving, Tx), 3.Comparative genome hybridization (Oncopath, San Antonio, TX). 4. Single-gene PCR assays,  PTEN  IHC (MDACC CLIA), 5. UT Houston morphoproteomics (Housto
Read more

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

Image
Versican is a potential therapeutic target in docetaxel-resistant prostate cancer ABSTRACT In the current study, we investigated a combination of docetaxel and thalidomide (DT therapy) in castration-resistant prostate cancer (CRPC) patients. We identified marker genes that predict the effect of DT therapy. Using an androgen-insensitive PC3 cell line, we established a docetaxel-resistant PC-3 cell line (DR-PC3). In DR-PC3 cells, DT therapy stronger inhibited proliferation/viability than docetaxel alone. Based on gene ontology analysis, we found versican as a selective gene. This result with the findings of cDNA microarray and validated by quantitative RT-PCR. In addition, the effect of DT therapy on cell viability was the same as the effect of docetaxel plus versican siRNA. In other words, silencing of versican can substitute for thalidomide. In the clinical setting, versican expression in prostate biopsy samples (before DT therapy) correlated with PSA reduction after DT therapy (p<0
Read more